StemCell Therapy

Transparency Market Research (TMR) has published a new report titled, Joint Pain Injections Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, theglobal joint pain injections marketis expected to exceed a value of US$ 3 Bn by the end of 2018. The global market is anticipated to surpass US$ 6 Bn by 2026 and expand at a high single digit CAGR from 2018 to 2026. Rise in number of geriatric patients, increase in awareness regarding joint disorders, and high unmet medical needs are expected to augment the global market from 2018 to 2026. The joint pain injections market is projected to expand, owing to an increase in the prevalence of joint pain among the population, demand for better treatments, and development of healthcare infrastructure in various countries across the globe.

Increasing prevalence of arthritis and other bone-related disorders

According to facts published by Arthritis Foundation, arthritis is the leading cause of disability among adults in the U.S. Approximately 54 million adults and 300,000 babies and children in the U.S. suffer from arthritis or any rheumatic condition. More than 78 million people in the U.S. are likely to suffer from doctor-diagnosed arthritis by 2040. Furthermore, osteoarthritis is the most common type of arthritis and affects approximately 31 million people in the U.S. Increasing prevalence of arthritis further boosts the demand for disease modifying treatments, which in turn is anticipated to propel the joint pain injections market during forecast period.

Request Brochure of Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47664

Increase in prevalence of obesity leading to joint pain

Obesity is considered a risk factor for various joint disorders, especially related to knee, such as knee pain and knee osteoarthritis. According to the fact sheet published by World Health Organization (WHO), worldwide obesity has tripled since 1975. In 2016. 1.9 billion People were overweight and among them, more than 650 million adults were obese. Moreover, approximately 41 million children under the age of 5 were obese in 2016. According to the 2015-2016 National Health and Nutrition Examination Survey (NHANES), more than one in four children of Hispanic origin ages 2 to 19 had obesity, and approximately 47% of adults suffered from obesity. Increasing patient pool in developing countries as well as developed countries is estimated to propel healthcare spending for joint pain treatments in these countries and consequently, drive the joint pain injections market.

Request for Analysis of COVID-19 Impact on Joint Pain Injections Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=47664

High unmet needs in patients with joint pain

Arthritis is the most common cause of joint pain and a major cause of disability and impaired mobility among the population. Currently available treatment options are insufficient, as they primarily focus on symptom relief and pain mitigation. There are no drugs available that can cure, reverse, or halt disease progression such as osteoarthritis. Moreover, some patients are unable to find relief with available treatments and continue to suffer in pain; therefore, there are large unmet needs in patients with joint pain. This provides opportunity for advance treatment options in the joint pain injections market.

Hyaluronic acid injections segment dominates the global market due to increasing acceptance for the treatment of osteoarthritis

In terms of injection type, hyaluronic acid injections is a highly attractive segment of the global joint pain injections market, followed by corticosteroid injections and others segments. This is attributable to the effectiveness of hyaluronic acid injections in the treatment of knee osteoarthritis, where other treatments are contraindicated.According to rapid response report published by CADTH, viscosupplementation with hyaluronic acid in adults with knee osteoarthritis is superior to intra-articular placebo and other conventional medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), in terms of improving knee pain and function with minimum adverse effects.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=47664

North America dominates the global market owing to high acceptance of viscosupplementation in the region

North America dominates the global joint pain injections market due to a large patient pool, increase in the geriatric population, increased obesity, and high acceptance of advanced treatments for the joint pain relief in the region. The region is estimated to maintain its dominance during the forecast period. Viscosupplementation with hyaluronic acid products is approved by US FDA for the treatment of knee osteoarthritis. Moreover, rising healthcare expenditure and increasing investments are key factors that are anticipated to boost the joint pain injections market in the next few years. The joint pain injections market in Asia Pacific is projected to expand at a notable CAGR due to increasing about join disorders in developing countries and rising research initiatives and manufacturing of hyaluronic acid products in Japan.

Buy Joint Pain Injections Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=47664&ltype=S

Investments by key players is driving the globaljoint pain injections market

Major players operating in the joint pain injections market include Allergan Plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Flexion Therapeutics, Inc., Zimmer Biomet Holdings, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

View original post here:
Joint Pain Injections Market: Investments by key players is driving the global market - BioSpace

Arthritis pain can lead to a number of debilitating symptoms that patients will want to try and avoid.

The condition can make life more difficult when carrying out simply, everyday tasks.

It's crucial that if you develop signs of arthritis, you speak to a doctor as soon as possible to try and find a treatment to relieve your pain.

One of the best ways to avoid arthritis pain is to eat more onions, it's been claimed.

READ MORE: Arthritis pain - the best vegetable to lower your risk of joint pain

"While the cure for arthritis eludes medical science, there are many potent treatments for the condition," it said.

"Chief among these are avoiding foods that exacerbate joint pain and eating foods that reduce it.

"Loaded with immune-boosting properties, garlic and onions are the superhero duo of the produce section.

"Studies have shown that those who eat foods in the allium family, such as garlic and onions, exhibit fewer signs of osteoarthritis and joint pain."

Common arthritis symptoms include joint pain, inflammation, and restricted movement.

There are two key types of arthritis in the UK; osteoarthritis and rheumatoid arthritis.

Osteoarthritis is the most common type of arthritis to be diagnosed in the UK - around nine million people are believed to have osteoarthritis.

Rheumatoid arthritis, meanwhile, is an auto-immune disease that has been diagnosed in about 400,000 individuals.

Follow this link:
Arthritis pain - the 90p 'superhero' vegetable you should add to your diet for joint pain - Express

About one in three people between ages 18 and 64 have some type of arthritis.

This common joint disease can wreak havoc on everyday life, but there are some ways to protect yourself.

Its coverage affecting your health.

Running, jumping and climbing stairs or mountains, your joints take a lot of abuse over time. It can lead to osteoarthritis and its not just a disease for the old.

Were seeing arthritis at an earlier age, not only in the knees, but shoulders, really everywhere. Its becoming an epidemic of sorts, said Dr. Matthew Pombo, MD, Emory Orthopedics and Spine Center.

So you can safe guard your joints?

First ditch the high heels as they put pressure on your knees and feet. A three inch heel stresses your foot seven times more than a one inch heel.

You might also want to scrap the sodas. A Harvard study found that men with osteoarthritis who drank more sugary carbonated drinks reported worse symptoms.

You might also want to get active, but ramp it up slowly and be careful of injuries.

We also have a lot of younger people participating in sports and we know that prior injury leads to post-traumatic arthritis, said Dr. Pombo.

Low impact activities such as walking, swimming and biking are best and extra weight is one of the biggest culprits for arthritis pain.

Every additional pound you gain puts four times the stress on your knees.

Research shows that losing as few as eleven pounds cuts your risk for osteoarthritis by 50% with ways to protect your joints.

See the original post:
Your Health: How to protect your joints from arthritis - YourErie

What did Bye set out to achieve?

According to Bye, numerous studies show that high-intensity interval training is much more effective for improving endurance than moderate intensity training.

"This is true regardless if you're sick or healthy, young or old. We wanted to see if patients with arthritis could handle high intensity training and see the same positive effects," said Bye.

After ten weeks of hard training on a spinning bike twice a week, Bye saw no adverse effects on her study's participants, a group of women with arthritis.

"Rather, we saw a tendency for there to be less inflammation, at least as measured by the inflammation marker CRP, and the participants of the study experienced a solid increase in maximum oxygen intake, meaning that they reduced their risk of cardiovascular disease," Bye said.

The participants also saw a small reduction in BMI, body fat percent and waist measurement, as well as an increase in muscle mass as a result of the training period.

The participants warmed up for ten minutes at 70 per cent of their maximum pulse, and then did four repetitions of high intensity (85-95 percent of max pulse) four-minute intervals.

The break between each interval was about three minutes, at 70 percent of max pulse. The total work-out session lasted about 35 minutes.

"The women who participated in the study found this to be a good, effective method of training, and are mostly very motivated to continue because of the progress they've seen," Bye concluded.

The NHS issues important advice when it comes to trying out different forms of exercise.

"If a particular activity causes your joints to become warm and swollen, or it causes severe pain, then stop and rest," says the health body.

If it does not cause problems, then it is usually fine to continue, notes the health site.

It adds: "If a particular activity always causes a flare-up, it's best to avoid it and find an alternative."

Read the original post:
Rheumatoid arthritis treatment: The fast workout that may provide pain relief - Express

Postpartum Arthritis: What to do if you are suffering from joint pain after delivery Pledge Times

No Result

View All Result

Let us know the causes of arthritis after delivery and what treatment options are available.

Arthritis after pregnancyArthritis can be troublesome at any age and the disease affects more women than men. Complaints of arthritis may increase after pregnancy, and some women continue to have arthritis pain after delivery. Arthritis can occur after delivery in the wrist, hands, ankles and feet.Cause of postpartum arthritisArthritis after delivery is called postpartum arthritis. The following reasons of arthritis of the child can be:Women who have arthritis before pregnancy can be relieved during pregnancy. Most autoimmune diseases such as rheumatoid arthritis or psoriatic arthritis disappear during pregnancy. This is due to antibodies and immune responses. Symptoms of arthritis may return after delivery.The immune system usually becomes strong after pregnancy. Any pre-allergic or autoimmune diseases such as rheumatoid arthritis can cause lupus due to the hyperactivity of the immune system.Age, obesity, jeans, lack of physical activity, smoking, infection and lack of nutrients in the diet can also cause arthritis or joint pain after pregnancy.Treatment of postpartum arthritisTell a doctor if you are complaining of joint pain or arthritis after delivery. Doctors can give treatment to reduce pain, reduce damage to joints. For this, you will have to go to the doctor periodically for a checkup.Apart from this, it is also very important to have a balanced and nutritious diet. Take calories, burn fat. If you have gained weight after delivery, weight loss can also relieve joint pain. When the weight is high, there is pressure on the erect joints especially on the axes and knees. Overweight increases the risk of arthritis.Being physically active can help reduce pain and improve mood. It also protects against long-term conditions like diabetes, high BP.

Conceive with arthritisThe 2011 study included approximately 74,000 pregnant women. All these women were suffering from Rheumatoid Arthritis and were having difficulty convalescing like normal women. About twenty five percent of these women were trying to conceive for about a year before becoming pregnant. Among women who did not suffer from rheumatoid arthritis, this figure was only sixteen percent.It is very important to control arthritis for at least 3 to 6 months before becoming pregnant.

.

Enneagram 7. The multi-tasker. Growing one step closer every day to leaving my legacy.

No Result

View All Result

Excerpt from:
Postpartum Arthritis: What to do if you are suffering from joint pain after delivery - Pledge Times

Global Arthritis Therapeutics Marketwas valued USD XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 4.8 % during forecast period of 2019 to 2026.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/36112

Global Arthritis Therapeutics MarketThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Arthritis is an inflammatory disorder affecting the joints cause redness, stiffness, resulting in pain and swelling in the joints. More than 100 categories of arthritis are affecting the global population. The most common arthritis conditions are psoriatic arthritis, rheumatoid arthritis, and osteoarthritis. The osteoarthritis affects a majority of the geriatric population, in severe joint pain and affecting their movement. Psoriatic Arthritis therapeutics contains drugs that help to reduce pain and inflammation.

Global Arthritis Therapeutic Market Drivers and RestrainsThe significant growth of the global arthritis therapeutics market is credited to investments in research & development, strong product pipeline, increasing patient pool suffering from arthritis. Furthermore, rise in the geriatric population is another factor fueling the growth of the global arthritis therapeutics market. Patients gone under treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) are unsatisfied because of poor therapeutic benefits. The dominance of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are the factors that boost the growth of global arthritis therapeutics market. In 2016, the International Federation of Psoriasis Association (IFPA) states that more than 125 Mn people were affected with psoriasis. It is estimated that between 11% and 32% of patients with psoriasis incline to develop psoriatic arthritis. Furthermore, nearly 52.2 million adults suffered from arthritis in U.S. alone in 2015. Developments in diagnostics and healthcare infrastructure in developing countries are projected to witness an increased number of diagnosed patients.

Manufacturers in the Arthritis Therapeutic are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Arthritis Therapeutic Market Segmentation AnalysisBy Arthritis Therapeutic Market is segmented into Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout and Others. Rheumatoid Arthritis and Psoriatic Arthritis segment is expected to exhibit highest global market share at a CAGR of xx% over forecast period. Increasing occurrence of arthritis diseases globally, is likely to drive key players to develop novel therapeutics treatment for the disease. Strong research and development by key companies supported by huge investments is projected to drive the global arthritis therapeutics market. In 2018, according to the WHO statistics 9.9 % of men AND 18.1 % of women over the age of 60 suffered from osteoarthritis, symptomatic, worldwide. About 80 % of those with osteoarthritis have limitations in movement, and 25 % of women over the age of 60 suffered from symptomatic osteoarthritis, globally.

Global Arthritis Therapeutic Market Regional AnalysisThe Global Arthritis Therapeutic Market has been classified into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America dominated the global arthritis therapeutics market, followed by Europe. Because of a large patient pool suffering from arthritis diseases, like osteoarthritis, rheumatoid arthritis and other conditions. Advantageous reimbursement policies, launching of novel biologics drugs, well-defined regulatory framework, and availability of biosimilars are boost up the market growth in the region. Furthermore, the presence of key players in the region and a strong product pipeline for arthritis treatment are projected to drive the arthritis therapeutics market in the region. This can be ascribed to awareness about arthritis, presence of key players, growing patient pool, favorable reimbursement policies, and availability of biosimilar and biologics arthritis drugs in the region.

The objective of the report is to present comprehensive analysis of Global Arthritis Therapeutic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Arthritis Therapeutic Market dynamics, structure by analyzing the market segments, and project the Global Arthritis Therapeutic Market size. Clear representation of competitive analysis of key players by Arthritis Therapeutic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Arthritis Therapeutic Market make the report investors guide.Scope of the Global Arthritis Therapeutic Market

Global Arthritis Therapeutic Market, by Type

Psoriatic Arthritis Rheumatoid Arthritis Osteoarthritis Gout OthersGlobal Arthritis Therapeutic Market, by Drug Class

TNF Inhibitors Interleukin Inhibitors NSAIDs Corticosteroids Xanthine Oxidase Inhibitors OthersGlobal Arthritis Therapeutic Market by Route of Administration

Oral Parenteral TopicalGlobal Arthritis Therapeutic Market, by Distribution Channel

Hospital Pharmacies Retail Pharmacies Online PharmaciesGlobal Arthritis Therapeutic Market, by Region

Asia Pacific North America Europe Latin America Middle East AfricaGlobal Arthritis Therapeutic Market, Major Players

Pfizer Inc. Bristol Myers Squibb Abbvie Inc. Astrazeneca Pharma Ucb Pharma Genentech Janssen Pharmaceutical Immunex Corp. Medac Pharma Boehringer Ingelheim Novartis, Biogen Eli Lilly And Company Astellas Pharma Mallinckrodt Roche Vertex Pharmaceutical

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/global-arthritis-therapeutic-market/36112/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Continued here:
Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026) - Galus Australis

Rheumatoid Arthritis Therapeutics Market Scenario 2020-2028:

The analysis of the market provides the global market dynamics and trends of the Rheumatoid Arthritis Therapeutics Market. The market study offers current and future outlook of the Rheumatoid Arthritis Therapeutics Market over the forecast period.

The analysis of the market provides an exhaustive overview with detailed growth scenarios and market potential with accurate market drivers and maximum forecast precision. The report comprises of exclusive and important factors that are likely to have a major impact on the Rheumatoid Arthritis Therapeutics Market throughout the forecast period. This study of the market includes a thorough and considerable amount of addition, which will help new entrants in the most comprehensive manner for better understanding. Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-68410?utm_source= SNG/KK

The analysis of the market commences with the executive summary of the Rheumatoid Arthritis Therapeutics Market study, which includes key findings and key information on the market. It includes market value share for the foremost segments in the Rheumatoid Arthritis Therapeutics Market. In addition, this section includes demand-side trends, supply-side trends, and recommendations for the Rheumatoid Arthritis Therapeutics Market.

Market Segmentation-

Based on the study the Rheumatoid Arthritis Therapeutics Market is segmented by By Molecule Type (Biopharmaceuticals (Biologics, Biosimilars), Pharmaceuticals), By Sales Channel (Prescription, OTC) This information can lead to a focused approach leading to better opportunities being found.

Based on the region, the Rheumatoid Arthritis Therapeutics Market has been categorized into North America, Europe, Asia Pacific, Middle East, and the Rest of the world. It also consists of detailed information regarding developments, key market trends, and market analysis in the Rheumatoid Arthritis Therapeutics Market based on region. The North America and Western Europe regions are estimated to register a stable demand during the forecast period with market recovery from recent slowdowns.

North America region includes the US, Canada, and Mexico. The US is estimated to dominate this market with a sizeable share followed by Canada, and Mexico. The industrial sector is a major contributor to the US and Canada economies overall. Hence, the supply of advanced materials in production activities is critical to the overall growth of industries in this region.

Get ToC for the overview of the premium report https://www.quincemarketinsights.com/request-toc-68410?utm_source=SNG/KK

The Rheumatoid Arthritis Therapeutics Market report examines the potential of the market in the key geographical region:

Speak to analyst before buying this report https://www.quincemarketinsights.com/enquiry-before-buying-68410?utm_source=SNG/KK

Competitive Analysis

The report includes a comprehensive list of all the leading manufacturers in the Rheumatoid Arthritis Therapeutics Market, along with detailed information about each company, which includes the company overview, revenue share, strategic overview, and recent company developments. Market players featured in this report include AbbVie;Boehringer Ingelheim GmbH;Novartis AG; Regeneron Pharmaceuticals, Inc.;Pfizer, Inc.; Bristol-Myers Squibb Company;F. Hoffmann-La Roche Ltd.;UCB S.A.; Johnson & Johnson Services, Inc.; andAmgen, Inc.. A detailed view of the competitive landscape covers future capabilities, key mergers & acquisitions, new product releases, new product innovations, etc.

Reasons why you should buy this report:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

View original post here:
Rheumatoid Arthritis Therapeutics Market : Opportunities, Demand and Forecasts, 2020-2028 - StartupNG

LOS ANGELES, Aug. 31, 2020 /PRNewswire/ -- Arrow Organics offers a wide range of premium CBD products. In an industry full of new competition and subpar transparency, Arrow Organics doubled down on science based CBD by pairing up with Alex Laughlin, a Biology PhD candidate from Cornell University. "After reviewing countless scientific case studies on CBD's efficacy in helping arthritis pains and sports injuries, we sought out the help of Alex Laughlin, MSc to carefully choose which formulas would give our customers the best relief," said Luke Paschal, CEO of Arrow Organics.

Arrow Organics recently launched two new topical CBD rubs formulated to provide relief from sore and injured muscles and joints by reducing inflammation to affected areas. "The ingredients in both the Intensive Relief Rub and Athletic Freeze Rub were specifically chosen for their ability to ease arthritis pain and muscle aches. "Coupling CBD's powerful effects with the specific ingredients of both creams have been shown to greatly reduce pain in various forms," said Laughlin.

Slow moving regulation hands the responsibility off to consumers on choosing the correct CBD company. The consumer must be educated on what types of CBD they're buying, if the lab reports are consistent with labeling, and how to properly use CBD. You can visit Arrow Organics website to view lab reports and get educated on CBD. "We happily welcome any questions about CBD, please feel free to reach out through our website or through email ([emailprotected])" Paschal.

Arrow Organics is currently offering free shipping nationwide as well as 20% off your next order with code "ARROW20".

Photo(s):https://www.prlog.org/12836149

Press release distributed by PRLog

SOURCE Arrow Organics

Read the original here:
Arrow Organics Commits to Science Based Full Spectrum Blends By Partnering with Ivy League Scientist - PRNewswire

NORTH CHICAGO, Ill., Aug. 25, 2020 /PRNewswire/ -- AbbVie(NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis. AbbVie also submitted an application to the European Medicines Agency (EMA) for RINVOQ earlier this year for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.

"Ankylosing spondylitis is a debilitating disease that can cause severe pain, restricted mobility and lasting structural damage. With limited treatment options, innovation is crucial to help more patients living with active ankylosing spondylitis reach their treatment goals," said Michael Severino, M.D., vice chairman and president, AbbVie. "RINVOQ has the potential to improve care by helping to provide disease control, addressing pain and improving function. We look forward to working with regulatory authorities and hope to bring this important treatment option to patients."

The applications to the FDA and EMA are supported by data from SELECT-AXIS 1, a Phase 2/3 study in which RINVOQ demonstrated significant improvements in signs and symptoms in patients with active ankylosing spondylitis.1 In this study, twice as many patients receiving RINVOQ (52 percent) met the primary endpoint of Assessment of SpondyloArthritis International Society (ASAS) 40 response versus placebo (26 percent) at week 14 (p<0.001).1 The safety profile of RINVOQ in ankylosing spondylitis was consistent with previously reported studies across therapeutic areas, including rheumatoid arthritis, atopic dermatitis and psoriatic arthritis, with no new significant safety risks detected.2-4

Ankylosing spondylitis is a chronic, progressive, inflammatory musculoskeletal disease impacting more than five million people worldwide.5,6 The range of symptoms pose significant physical, psychological and economic burden on individuals impacted by the disease.5,7-9

About RINVOQ (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.10-17 In August 2019, RINVOQ received U.S. FDA approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ was approved by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. The approved dose for RINVOQ in rheumatoid arthritis is 15 mg. Phase 3 trials of RINVOQ in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn's disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing.12-17 Use of RINVOQ in ankylosing spondylitis is not approved and its safety and efficacy have not been established by regulatory authorities.

Important Safety Information about RINVOQ (upadacitinib)18

RINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.

What is the most important information I should know about RINVOQ?RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.

What should I tell my HCP BEFORE starting RINVOQ?Tell your HCP if you:

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.

What should I tell my HCP AFTER starting RINVOQ?Tell your HCP right away if you:

What are the common side effects of RINVOQ?These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.

RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. Please click here for theFull Prescribing InformationandMedication Guide. Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Rheumatology

For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals. For more information on AbbVie in rheumatology, visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie on Twitter,Facebook,Instagram,YouTubeandLinkedIn.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

View original content:http://www.prnewswire.com/news-releases/abbvie-submits-regulatory-application-to-fda-for-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis-301117875.html

SOURCE AbbVie

See the article here:
AbbVie Submits Regulatory Application to FDA for RINVOQ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis - BioSpace

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Psoriatic Arthritis Therapeutics Market market.

Trusted Business Insights presents an updated and Latest Study on Psoriatic Arthritis Therapeutics Market Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Psoriatic Arthritis Therapeutics Market market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Global Psoriatic Arthritis Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global Psoriatic Arthritis Therapeutics market report has been segmented on the basis of drug, diseases type, and region.

Request Covid 19 Impact

Global Psoriatic Arthritis Therapeutics Market: Overview

Psoriatic arthritis (PsA) is a type of chronic disease, characterized by inflammation in the joints and skin. This disease is progressive category of diseases that may worsening over time. If left untreated, this psoriatic arthritis may lead to joint damage permanently. It is characterized by potential involvement of diverse tissues, including, enthesitis, peripheral and axial joints, skin & nail disease, and dactylitis. The treatment of PsA includes the use of a variety of interventions that act as an agent for the treatment of patients with other forms of inflammatory arthritis, such as rheumatoid arthritis (RA), spondyloarthritis and others.

Global Psoriatic Arthritis Therapeutics Market: Dynamics

Increasing number of cases of psoriatic arthritis especially in elderly population is a key factor expected to drive the growth of the global market over the forecast period. In addition, rising awareness about psoriatic arthritis treatment among the healthcare professionals and increasing elderly population. The above mentioned are some of the other factors expected to drive growth revenue of the global market. However, high cost of the drugs and treatment, entry of biosimilar drug in the market, and lack of standardization tools for diagnosis and treatment. These are some of the major factors expected to hamper growth of the target market to a certain extent.

Global Psoriatic Arthritis Therapeutics Market: Segment Analysis

Among the drug type segments, Nonsteroidal anti-inflammatory drug is estimated to account for majority of revenue share in the global market. This is due to, rising prescribing of NSAID drugs for patients, in order to pain and morning stiffness, controlling swelling, and to improve range of motion to joints.

Among the diseases type segments, symmetric psoriatic arthritis is estimated to hold highest revenue and register highest CAGR over the forecast period, due to increasing number of cases of affecting several joints in pairs on both sides of your body. It may damage joints over time, that can lead to limited movement and function of body.

Global Psoriatic Arthritis Therapeutics Market: Trends

The established players are adopting various growth strategies such as partnership, collaboration, mergers, new product launch etc., in order to cater the growing demand for Psoriatic Arthritis Therapeutics globally. In addition, the prominent players are collaborating with local player in order to form string value and supply chain. The aforementioned are some of the current key trend witnessed in the target market.

Global Psoriatic Arthritis Therapeutics Market: Regional Analysis

In 2019, the markets in North America estimated to account for highest market revenue share in the target market over the forecast period. This is primarily attributed to, increasing incidences of psoriatic arthritis. According to RheumatoidArthritis.org, which is a non-profit team of healthcare professionals around 85% of individuals living with psoriatic arthritis in US. The markets in Asia Pacific accounted for highest CAGR over the forecast period, owing to increasing prevalence and incidences in the temperate zones in the region, and growing healthcare expenditure. In addition, higher demand and increased rate of adoption of biologic drugs in countries such as Australia & New Zealand, are projected to drive the psoriatic arthritis therapeutics market in Asia Pacific region.

Global Psoriatic Arthritis Therapeutics Market Segmentation:

Segmentation by drug:

Nonsteroidal anti-inflammatory drug (NSAID)Disease-modifying antirheumatic drug (DMARD)Biologic drugEnzyme inhibitor

Segmentation by diseases type:

Asymmetric Psoriatic ArthritisSymmetric Psoriatic ArthritisDistal Interphalangeal Predominant (Dip) Psoriatic ArthritisSpondylitisArthritis Mutilans

Looking for more? Check out our repository for all available reports on Psoriatic Arthritis Therapeutics Market in related sectors.

Quick Read Table of Contents of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Visit link:
Global Psoriatic Arthritis Therapeutics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To...

The researchers wanted to turn those awakened stem cells into cartilage. The recipe that worked was to treat the stem cells with bone morphogenetic protein, which is used to help fuse bones.

The scientists also used a drug called Avastin, which prevents the stem cells from getting a blood supply. Unlike bone and bone marrow, cartilage has no blood supply, and the drug helped stimulate the stem cells to turn into cartilage.

The investigators provided the drugs directly to the ends of bones, putting them in a gel.

The cartilage that grew in the mice not only looked like normal but lasted for four months, a quarter of the animals lifetimes. Dr. Chan and Dr. Longaker envision a time when doctors will be able to resurface arthritic joints or, even better, to treat people who are just beginning to develop arthritis, perhaps staving off the sort of damage that even joint replacements cannot fix.

If the strategy works in humans, then early treatment may be the best approach, Dr. Marx said.

Arthritis deforms joints and changes bones, he said. By the time people have hips or knees replaced, irreversible damage may be done. Legs may be bowed, bones damaged.

You cannot totally turn back the clock, Dr. Marx said. At that point, he said, adding cartilage will not fix it.

He worries, though, that orthopedists may not wait for rigorous studies the method of awakening the dormant cells is relatively simple, and the drugs required are already on the market.

Faced with a patient with aching knees, orthopedists may be tempted to say, Lets try this. You dont have much to lose, Dr. Marx noted.

Continue reading here:
Cartilage Is Grown in the Arthritic Joints of Mice - The New York Times

Treat-to-target and safe tapering strategies should continue to be essential in the management of rheumatoid arthritis (RA) during the coronavirus disease 2019 (COVID-19) pandemic, according to a commentary published in Lancet Rheumatology.

The National Institute for Health and Care Excellence COVID-19 guidelines suggested that face-to-face patient consultations should be avoided, unless patients present with a disease flare; patients with stable disease should be treated remotely. However, the definition of stable disease may be misguided, the authors of the commentary noted. Even amid the pandemic, treat-to-target strategies should be preserved to maximize the number of patients achieving remission.

Treat-to-target refers to arthritis management that prioritizes low disease activity or remission. With treat-to-target, patients set specific management targets and undergo frequent laboratory tests and clinical examinations. If disease targets are not met, different treatment strategies are adopted. Research has suggested that up to 50% of patients can achieve remission through treat-to-target.

While focused efforts may be taken to mitigate COVID-19 risk, rheumatologists should prioritize treat-to-target for their patients. Although patients with minimal disease activity or remission may be good candidates for remote management, patients who have yet to reach their treatment goals should be considered for clinic visits.

Patients undergoing dose tapering may also require clinic visits, the authors added. Clinical examination of the joints is often necessary to detect flares. In addition, in the context of the pandemic, some patients may be self-tapering because of fears of their drugs increasing the risk for COVID-19. While early observational data has suggested that disease-modifying antirheumatic drugs do not increase risk for COVID-19, research is still ongoing. Clinicians should make every effort to monitor patients who are tapering and minimize the risk for disease flares.

Ideally, development of one-stop shop clinics may be the best way to manage RA while minimizing hospital contact. While efforts to maintain physical distancing are essential, patients with RA should not have to endure disease flares as a result.

Treat-to-target and safe tapering strategies should continue to be essential in the management of rheumatoid arthritis, regardless of new approaches that streamline the patient experience and reduce the number of hospital visits, the authors concluded.

Yeoh SA, Ehrenstein MR. Are treat-to-target and dose tapering strategies for rheumatoid arthritis possible during the COVID-19 pandemic? Lancet Rheumatol. 2020;2(8):e454-e456.

See more here:
Maintaining Treat-to-Target Strategies for Rheumatoid Arthritis During the COVID-19 Pandemic - Rheumatology Advisor

Arthritis pain can lead to a number of debilitating symptoms that patients will want to try and avoid.

The condition can make life more difficult when carrying out simply, everyday tasks.

It's crucial that if you develop signs of arthritis, you speak to a doctor as soon as possible to try and find a treatment to relieve your pain.

One of the best ways to avoid arthritis pain is to eat more broccoli, it's been claimed.

READ MORE: Arthritis pain - common household sauce you should avoid

"Although there is no diet cure for arthritis, certain foods have been shown to fight inflammation, strengthen bones and boost the immune system," said the Arthritis Foundation of Asia.

"Adding these foods to your balanced diet may help ease the symptoms of your arthritis.

"Rich in vitamins K and C, broccoli also contains a compound called sulforaphane, which researchers have found could help prevent or slow the progression of osteoarthritis.

"Broccoli is also rich in calcium, which is known for its bone-building benefits."

You could also lower your risk of arthritis by eating more red beans, added the Arthritis Foundation.

They could lower your chances of arthritis symptoms as they're rich in fibre.

Fibre is a crucial nutrient that helps to lower the amount of C-reactive proteins in the body.

These proteins are a marker of inflammation, which have been linked to heart disease, diabetes, and even rheumatoid arthritis.

Common arthritis symptoms include joint pain, inflammation, and restricted movement.

There are two key types of arthritis in the UK; osteoarthritis and rheumatoid arthritis.

Osteoarthritis is the most common type of arthritis to be diagnosed in the UK - around nine million people are believed to have osteoarthritis.

Rheumatoid arthritis, meanwhile, is an auto-immune disease that has been diagnosed in about 400,000 individuals.

Follow this link:
Arthritis pain - the best vegetable to lower your risk of joint pain and inflammation - Express

The incidence and prevalence of rheumatoid arthritis (RA), the most common autoimmune inflammatory arthritis, is increasing worldwide; in 2014, RA affected an estimated 1.28 to 1.36 million adults.1 A growing body of research has indicated that compared with patients without RA, those with RA are disproportionately affected by psychiatric disorders, particularly anxiety and depression.2,3 Psychiatric disorders in patients with RA not only affect functioning and quality of life, but they have been associated with poorer RA outcomes, including a greater frequency of flares, lower odds of achieving remission, and increased mortality.4

Psychiatric comorbidities in RA lead to higher rates of healthcare utilization. In a retrospective cohort study by Carol Hitchon, MD MSc, clinician scientist at the University of Manitoba in Winnipeg, Canada, and colleagues,5 an analysis of health records of 12,984 patients with RA and 64,510 matched control participants for the period between 2006 and 2016 showed that patients with RA with vs without comorbid psychiatric disorders (depression, anxiety, bipolar disorder, or schizophrenia) received more types of medications, had more ambulatory physician visits and hospitalizations, and greater length of hospital stays. Investigators concluded that managing psychiatric comorbidities effectively may reduce utilization among patients with RA.

We spoke with Dr Hitchon who suggested that the presence of psychiatric disorders can complicate treatment decisions and subsequent outcomes. We know that psychiatric comorbidity [affects] how people experience pain and this may or may not be associated with joint inflammation, she added. This type of pain may be treated differently than if the pain is due to joint inflammation. Psychiatric disorders can also complicate the assessment of RA activity, since low mood or depression can influence the patient-reported components of standardized instruments such as disease activity score in 28 joints.6

Depression, the most common psychiatric comorbidity of RA, has been estimated to occur in 9.5% to 41.5% of patients with RA.2,7 A recent meta-analysis concluded that 16.8% of patients with RA had comorbid major depressive disorder (MDD), based on pooled estimates from studies that identified depression with psychiatric interviews, the gold standard for diagnosis.7 The reasons for the prevalence of depression in patients with RA typically include the adverse effects that chronic pain, fatigue, and functional limitations have on social roles and quality of life.4

We also spoke with Melissa Withers, PhD, MHS of the USC Institute on Inequalities in Global Health at the University of Southern California Keck School of Medicine, who noted that the pain and limitations associated with RA can negatively affect many aspects of patients lives. They may not be able to participate in the things that used to bring them joy, like hobbies, social interactions, or a job. Patients are especially at risk for depression and anxiety when they are first diagnosed with RA. You can imagine they hear that they are facing a debilitating, degenerative, long-term illness. So it can be very upsetting. It brings a lot of fear of what their futures will be like.

Shared inflammatory pathways are also widely believed play a role in the frequent co-occurrence of depression and RA. Studies have shown that proinflammatory cytokines implicated in RA, such as tumor necrosis factor (TNF) , interleukin (IL)-6 and IL-1, are overexpressed in patients with depression compared with healthy control participants.4 In addition to causing chronic joint inflammation and damage to the cartilage and bone, excessive levels of these cytokines may contribute to depression by having detrimental effects on neuroendocrine function, neurotransmitter metabolism, and brain structures. Increased serum and/or plasma concentrations of C-reactive protein, often seen in RA populations, are also present in patients with depression or anxiety.6

An analysis of audio recordings taken at patient visits for RA showed that rheumatologists rarely brought up the topic of depression, even among patients whose depressive symptoms were moderate to severe.8 Dr Withers recommended that rheumatologists incorporate depression identification and management into patient care plans, especially since patients may not know that a rheumatology visit is an appropriate time to bring up mental health issues. It is critical to screen patients regularly for depression and other disorders and to follow those with scores that suggest mild depression to determine if the depression worsens over time, she said. If the patient scores indicate depression or a psychiatric disorder, the rheumatologist can then refer them for consultation with a mental health professional.

Lekeisha Sumner, PhD, ABPP, a licensed clinical psychologist with a board certification in clinical health psychology and author of several papers on the psychosocial aspects of rheumatologic diseases, stated that depression and anxiety are grossly underdiagnosed and treated in rheumatologic diseases despite their high prevalence. The provider-patient relationship is key in health outcomes and especially important when discussing sensitive topics that have historically been stigmatized, she advised. Leveraging rapport with your patient to ask about how their emotional strain presents at each visit invites them to give voice to the often-silent suffering that they commonly experience. Keep in mind that some of your patients will likely have alexithymia, which not only complicates their recovery but makes it more difficult for them to identify and process their emotions. Dr Sumner recommended that rheumatologists use simple screening tools such as the Generalized Anxiety Disorder and Patient Health Questionnaire to assess mental health.

Conceptualizing symptoms of anxiety and depression as par for the course in RA conditions is ill-advised as they contribute to increased burden on the patient, diminishes overall functioning, increased pain sensitivity, affects long-term disease activity, remission, response to treatment, and quality of life, Dr Sumner noted. Recognize that your patient has likely experienced difficulties with sexual functioning, ability to earn a living and engage in daily activities with ease, resulting in shifts in identity and confidence to effectively self-manage their condition. Targeting immunologic alterations will help alleviate psychiatric distress, along with using a multidisciplinary approach to care that includes mental health professions are all key to disease management and promoting adaptive adjustment and coping.

The rest is here:
An Overview of Psychiatric Comorbidities in Rheumatoid Arthritis - Rheumatology Advisor

By: Lifestyle Desk | New Delhi | Updated: August 22, 2020 2:26:34 pmPeople who suffer from long standing arthritis of the joints find it difficult to move andwalk around because of pain. (Photo: Getty Images/Thinkstock)

Covid-19 pandemic has taught us the importance of being fit. It is a well-known fact that a healthy mind lives in a healthy body. Certain medical conditions like diabetes, obesity and hypertension need to be well controlled to have better immunity against infections.

People who are suffering from long-standing arthritis of the joints are not able to move and walk around because of pain and disability in their joints. This can lead to uncontrolled diabetes, hypertension, and weight gain because of less calorie expenditure. This can, in turn, weaken the bones and muscles of the limbs, causing a disease called osteoporosis. This complicates the whole situation because now these people are not only just suffering from arthritis but also osteoporosis and weak muscles. This leads to increased fragility of the bone and also instability while walking. These patients have an increased tendency to fall and we are witnessing many such patients with fractures around the hip and leg bones, Dr Subhash Jangid, director and unit head, Fortis bone and joint institute, Fortis Memorial Research Institute, Gurugram told indianexpress.com.

If someone is not able to move because of weak bones and arthritis, they should get themselves treated by medication or by surgery. That is because, if they get COVID-19 infection in such a situation, they may face a tough time recovering because of weak muscles (including chest muscles) and poor immunity. Taking multivitamins and other healthy foods are not just enough to boost immunity. Health experts have repeatedly emphasised on exercising every day, maybe just a brisk walk for 30 min every day.

So, if you are suffering from hip and knee arthritis, dont delay the surgery and prolong the suffering as it is a vicious cycle that will further cause deterioration in your health. We have to take precautions and stop fearing the pandemic. Precautions are the most important thing which can save us from this illness, Dr Jangid added.

Read| Have arthritis? Some of these exercises can help

Delaying your health needs will take a toll on the recovery as well and the results may be compromised. We are seeing a lot of patients with advanced diseases owing to the delay in surgery now that they are scared to step out. Your health and immunity are the only saviour against COVID-19 and we need to focus on the same, the doctor further said.

The biggest myth is that the hospitals are COVID-19 hot spots. If hospitals would have been hot spots, almost all medical staff would have been infected by now. But that is not what we are seeing all over the world. Actually, coronavirus is everywhere and the hospitals are one of the safest places because the guards against the virus are always on. People are getting the infection from the grocery stores and markets rather than from the hospitals. Everyone remains safe if they take precautions. And in hospitals, people take maximum precautions, Dr Jangid remarked.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

The Indian Express (P) Ltd

Go here to read the rest:
Covid-19 and arthritis: Why people with joint pain should not delay treatment - The Indian Express

The use of disease-modifying antirheumatic drugs (DMARDs) and the adoption of an early and aggressive treatment strategy have transformed the outcomes of patients with rheumatoid arthritis (RA). These immunosuppressive and immunomodulatory agents are essential to the comprehensive RA treatment strategy, with an objective of achieving disease remission or sustained minimal disease activity, to prevent radiographic progression.1

The DMARDs currently available are broadly categorized as conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs). Conventional synthetic DMARDs typically include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and are generally used in the first-line setting.2 Several bDMARDs are approved for RA in 6 therapeutic classes, including tumor necrosis factor inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab); T-cell costimulatory blocking agent (abatacept); B-cell depleting agents (rituximab); interleukin-1 receptor antagonists (anakinra); interleukin(IL)-6 inhibitors (tocilizumab and sarilumab); and Janus kinase inhibitors (JAK; tofacitinib, baricitinib, and upadacitinib).3 Biosimilars, a highly similar copy of the original approved biologic agent, with no clinically meaningful differences in safety, purity, and potency, has expanded the options of bDMARDs.4 In general, bDMARDs are prescribed after the failure of first-line csDMARD therapy.

The most commonly used csDMARD in the first-line setting is methotrexate. When RA progresses despite treatment with csDMARDs, a bDMARD may be introduced as monotherapy, typically in combination with a csDMARD, such as methotrexate. In cases of disease progression, despite treatment with methotrexate and bDMARDs, clinicians are faced with an increasingly challenging choice of treatment selection to achieve optimal disease management. Over time, 2 key questions have emerged: the comparative effectiveness of bDMARD monotherapy vs the combination of a bDMARD with methotrexate, and the comparative effectiveness of the available bDMARD either as monotherapy or in combination with methotrexate. The importance of these questions may be related to treatment efficacy and safety, given the diverse RA patient population among whom approximately one-third are treated with bDMARD monotherapy, primarily because of intolerance or noncompliance with methotrexate.5

The comparative effectiveness of bDMARD vs methotrexate monotherapy has been addressed in several studies. Overall, the superiority of bDMARD vs methotrexate monotherapy has been established for all 6 classes of bDMARDs, particularly in the setting of disease progression with methotrexate.6-9

With respect to the comparative effectiveness of bDMARD monotherapy vs combination with methotrexate, available studies have shown that some bDMARDs were more efficacious in combination with methotrexate, others as efficacious as either monotherapy or in combination, and the evidence for other DMARDs were less clear.

Specifically, the superiority of the efficacy of bDMARDs in combination with methotrexate compared to bDMARD monotherapy has been evident for tumor necrosis factor inhibitors (TNFis), but not non-TNFis.5,8 Both abatacept and tocilizumab have showed effectiveness whether combined with methotrexate or used as monotherapy.5,8,10 The effectiveness of rituximab as monotherapy compared to combination with methotrexate has been less clear, with some studies reporting superior efficacy as a combination,11-13 although the effectiveness either as monotherapy or in combination with methotrexate has also been reported.14 The use of tofacitinib in RA has been inconclusive because of lack of available data.5,15 Taken together, the evidence suggests that the currently available bDMARDs vs methotrexate monotherapy achieve greater control of disease activity. However, the combination of a bDMARD with methotrexate may be more efficacious than bDMARD monotherapy for anti-TNF agents, comparable for tocilizumab and abatacept, and inconclusive for rituximab, tofacitinib, and anakinra because of paucity of studies and data.

While it has been established that bDMARDs vs methotrexate may be more efficacious in disease control, the choice of available bDMARDs can be challenging because of the lack of head-to-head comparative studies and the limited data for use of these agents. The majority of the studies that have evaluated the comparative effectiveness of bDMARDs have concluded that anakinra may be the least efficacious.16 Furthermore, the American College of Rheumatology (ACR) response was found to be higher with tocilizumab compared to a TNFi or the JAK inhibitor tofacitinib.5 Among the TNFi agents, etanercept has been reported to be the most efficacious and infliximab the least.16,17 In combination with methotrexate, excluding anakinra, available data suggest comparable efficacy across the bDMARDs evaluated.10,18

A meaningful comparative effectiveness analysis of bDMARDs has been challenged by several limitations that question the accuracy of the comparisons.3 In many cases, there are variations in study design and clinical end points. Furthermore, available data may not be comparable for all agents; for example, there is fewer data for the newer approved agents such as the JAK inhibitors. Data has typically included heterogeneous, selected patient populations, with outdated definitions of clinical end points of clinical remission and low disease activity. Furthermore, in the absence of head-to-head studies, an indirect comparison of trial findings has often resulted in inconclusive analyses challenging clinical decision-making.

A recent systematic review and network meta-analysis by Janke et al provides a more rigorous comparative effectiveness analysis of the approved bDMARDs, using a method that included data from clinical study reports and reanalyses from individual patient data on key outcomes for RA, adopting the current definitions of clinical end points.3 This approach enabled a more homogeneous patient population for comparative analysis. The 34 studies that met the criteria for comparative effectiveness analyses included 10,869 patients and investigated 8 different biologic agents in combination with methotrexate (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab, anakinra, abatacept, and tocilizumab). However, the analysis did not include rituximab, or the more recently approved agents such as sarilumab, tofacitinib, baricitinib, and upadacitinib. Overall, as reported in previous studies, there were few statistically significant differences between the bDMARDs in combination with methotrexate in terms of benefits and harms.

Researchers found that anakinra was the least efficacious in clinical remission or low disease activity3; compared to anakinra, adalimumab, certolizumab pegol, and golimumab had statistically significant advantages for RA remission, and abatacept, adalimumab, infliximab, and tocilizumab were found to have statistically significant advantages for low disease activity.3 Regarding safety, certolizumab pegol had a higher risk for serious adverse events (compared to abatacept, adalimumab, anakinra, etanercept, and infliximab) and infections (compared to abatacept, anakinra, etanercept, golimumab, tocilizumab, and infliximab). The risk for serious infections was higher with infliximab compared to golimumab and tocilizumab. The discontinuation rate due to adverse events was higher for anakinra compared to abatacept, adalimumab, etanercept and infliximab, and higher for abatacept compared to tocilizumab.3 Despite the rigorous methodology of this study, the authors acknowledged the limited data for long-term direct comparisons between the bDMARDs, with a recommendation for routine availability of individual patient data.

Although the expansion of bDMARDs provides improved treatment options, selecting treatment for the optimal disease management has been challenging because of the limited robust comparative effectiveness studies available.

The recent rigorous study by Janke and colleagues suggest a small but statistically significant differences in disease remission, and serious adverse events between the biologic agents. From a clinical decision standpoint, it is important to individualize treatment, taking into consideration disease activity, comorbidities, and patient treatment preferences, while weighing the significance of the differences between the bDMARDs for disease management and outcomes.

Original post:
Comparing the Effectiveness of Biologic Agents in the Treatment of Rheumatoid Arthritis - Rheumatology Advisor

ENCINO, Calif., Aug. 24, 2020 /PRNewswire/ -- Mounting evidence is suggesting that the onset of mental illness might be due more to the presence of inflammation of the brain than just being a random or spontaneous condition. Chronic stress, traumatic and non-traumatic brain injuries and auto-immune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, Grave's and Hashimoto's diseases, and even Crohn's disease are known to precipitate inflammation and be associated with depression.

Common to each of these conditions is the production of a group of inflammatory chemicals produced by our immune system and called Cytokines (IL-1, IL-6, and TNF-alpha). These same chemicals are responsible for the lung and neurological damage associated with coronavirus (COVID-19). Studies have demonstrated in patients with auto-immune Psoriatic arthritis that when they are treated with a medication (etanercept) that blocks the inflammatory cytokine TNF-alpha, aside from improvement in the arthritis, there is a significant reduction in their depression.

This neuroinflammatory hypothesis for depression and other psychiatric illnesses explains substantially more than prior models, including why emergent data shows that when analgesics, anti-inflammatory medication, hormonal replenishment, pro-neurogenic, and pro-neurotrophic treatments are used, there are beneficial effects on depression.

The brain is contained within the skull and is surrounded by cerebrospinal fluid (CSF), whose composition is derived from lifestyle choices. Nutrition, water, drugs, alcohol, medication, and traumas all influence the quality of this CSF.When the CSF is healthy, the brain has more resiliency when challenged, but when unhealthy, the changes in its chemical make-up can precipitate cognitive and emotional illnesses. The Millennium Health Centers has been working since 2004 to correct unhealthy changes to the CSF and to influence how the brain can repair after trauma.

Read some of the science at: https://tbihelpnow.org/the-science

About Dr. Mark L. Gordon

Dr. Mark L. Gordon is the founder and medical director of Millennium Health Centers, Inc. in Encino, California. In 2015, Dr. Gordon released the book, "Traumatic Brain Injury - A Clinical Approach to Diagnosis and Treatment" that presents the science and his experience treating all precipitating causes of traumatic brain injury in both active military, veteran, sports, and civilian populations. Dr. Gordon has also joined with the Warrior Angels Foundation, a 501(c)(3) charitable organization founded by veterans Andrew and Adam Marr to provide medical services to members of the armed forces both active duty and veterans. For more information, visit TBIHelpNow.org.

About Millennium Health Centers, Inc

Since 2004, the Millennium Health Centers, Inc., under the direction of Dr. Mark L. Gordon, has worked to develop a diagnostic bio-marker panel and personalized treatment protocols for both traumatic and non-traumatic brain injuries associated with neuropsychiatric symptoms.

In 2015, the Millennium Health Centers, Inc. developed a neuro-regenerative program that involves the assessment and treatment of both traumatic and non-traumatic brain injury symptoms which may include depression, anxiety, lost libido, insomnia, migraines, obsessive-compulsive disorders, bipolar disorder, cognitive disorders, Parkinson's, and dementia conditions. Many of these can present years after the initial insult(s) which are frequently never considered.

Media Contact

Mark L. Gordon, M.D., Founder and Medical Director

[emailprotected]

SOURCE Millennium Health Centers, Inc

Read more from the original source:
Rethinking Mental Illness: A Response to Inflammation - PRNewswire

Compared with male patients, female patients with systemic juvenile idiopathic arthritis (JIA) have higher levels of genes related to circulating immature neutrophils, with these genes being associated with response to treatment, according to study results published in Journal of Leukocyte Biology.

The prevalence of systemic JIA has been estimated to be 3 times higher in female than male patients; female patients were also found to have lower rates of response to treatment.

The aim of the current study was to characterize blood gene signatures of 3 cohorts of male and female patients with JIA and assess the effect of sex on the whole blood transcriptomes of patients.

Researchers included clinical metadata from 451 patients and analyzed whole blood transcriptomic data of those with and without systemic JIA. They performed differential expression analyses for male and female patients, separately.

The number of differentially expressed genes was similar in male and female patients with systemic JIA compared with sex-matched control participants. However, because most differentially expressed genes were not shared between males and female patients, researchers suggested sexual dimorphism of systemic JIA at a molecular level.

There were a total of 44 genes whose fold-change expression was much higher in female vs male patients with systemic JIA compared with control participants. Of these genes, 18 were associated with neutrophil functions (adjusted P <.0001). In comparison, a total of 47 genes were highly induced in male patients with systemic JIA. Several of the genes associated with neutrophil functions were specific for female patients and were not expressed in male patients with systemic JIA.

Among the 44 genes in systemic JIA female-specific signature, 9 were highly expressed in neutrophil progenitor cells, suggesting that circulating immature neutrophils may be more positively activated or in higher numbers in female vs male patients with systemic JIA.

The potential effect of patient sex on levels of immature neutrophils in response to treatment with anti-interleukin-1 (anakinra) was assessed by comparing the expression of band neutrophils signature in female and male patients with systemic JIA after treatment. The data suggest that while in male patients there was no change in band neutrophils signature, in female patients compared with healthy control participants, the expression of band neutrophils was higher; expression of band neutrophils was even higher after the first month of treatment and only went down after 6 months of treatment.

Data also suggest that that this immature neutrophil signature is sexually dimorphic across the human lifespan and in adults with rheumatoid arthritis and asthma.

These results suggest that neutrophil maturation is sexually dimorphic in rheumatic inflammation, and that this may impact disease progression and treatment, the researchers concluded.

Prada-Medina CA, Peron JPS, Nakaya HI. Immature neutrophil signature associated with the sexual dimorphism of systemic juvenile idiopathic arthritis. Published online August 13, 2020. J Leukoc Biol. doi:10.1002/JLB.6MA0720-015RR

Read more:
Sexual Dimorphism of Systemic Juvenile Idiopathic Arthritis Linked to Immature Neutrophil Signature - Rheumatology Advisor

Fortune Business Insights Published Psoriatic Arthritis Treatment Market Report. The Psoriatic Arthritis Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

An Overview of the Impact of COVID-19 on Psoriatic Arthritis Treatment Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Market Highlights:

The report offers insights into the ongoing Psoriatic Arthritis Treatment market trends. The report provides forecast values for the market for the period of 2019-2026. It highlights leading companies in the market and discusses the strategies that these companies have adopted in recent years. The competitive landscape scenario has been discussed in detail. Factual figures have been evaluated through trusted sources. Other forecast values have been gathered through interviews and opinions of experienced market research professionals.

Global Continuous Renal Replacement market 2020 research provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Global Psoriatic Arthritis Treatment market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue, and gross margins.

The report also focuses on global major leading industry players of Global Psoriatic Arthritis Treatment market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The Global Psoriatic Arthritis Treatment Market Share and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Psoriatic Arthritis Treatment Market Forecast (2020-2026):

Psoriatic Arthritis Treatment Market Include the Following Manufacturers Based on Psoriatic Arthritis Treatment Sales, Revenue, Price and Gross Margin. The analysis of the Psoriatic Arthritis Treatment Market is a thorough study that offers a select combination of skillful market realities. The study shows changing trends of the market as well as the size of each separate segment in this market. Various product types and application are shown below.

Competition landscape of the global Psoriatic Arthritis Treatment market is brimming with private, commercial and government organizations, progressing towards introducing innovations in the field of life sciences with research & development activities. Established companies in the Psoriatic Arthritis Treatment market are exploring opportunities in developing nations like India to enhance their revenue gains.

Psoriatic Arthritis Treatment Market 2020 global industry research report is a professional and in-depth study on the Psoriatic Arthritis Treatment market trends, share, size, growth, as well as industry analysis. Furthermore, market size, the revenue shares of each segment and its sub-segments, as well as forecast figures are also covered in this report. Psoriatic Arthritis Treatment Market Forecast 2025 report study provides key statistics on the market status of the Psoriatic Arthritis Treatment manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Regions Covered in Psoriatic Arthritis Treatment Market Report:

The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Psoriatic Arthritis Treatment by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Table of Contents:

1 Market Overview

1.1 Psoriatic Arthritis Treatment Introduction

1.2 Market Analysis by Type

2 Manufacturers Profiles

3 Sales, Revenue and Market Share by Manufacturer

3.1 Global Psoriatic Arthritis Treatment Sales and Market Share by Manufacturer (2018-2019)

3.2 Global Psoriatic Arthritis Treatment Revenue and Market Share by Manufacturer (2018-2019)

3.3 Market Concentration Rate

3.4 Market Competition Trend

Continued

Related News:

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

Advanced Wound Care Market

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights Pvt. Ltd.

Supreme Headquarters,

Pune Banglore Highway, Baner, Pune,

Maharashtra 411045, India

Email: [emailprotected]

See the article here:
Psoriatic Arthritis Treatment Market 2020 Global Industry Analysis By Size, Trends, Share, With Regional Forecast To 2026 - The Daily Chronicle

Suffering from stiff, sore joints? You just might find relief in the form of plants. Studies have identified a number of spices that have anti-inflammatory benefits, and when eaten every day, can have an even greater impact on improving your overall health.

A 2018 study published in the Journal of Translational Medicine shows spices can help to reduce inflammation, which leads to joint pain and swelling.

They may also help prevent certain cancers and other chronic diseases like arthritis, asthma, and gastrointestinal disorders. Epidemiological studies show the rate of certain cancers in countries like Indiawhere spices are consumed on a daily basisare lower than in Western countries like the U.S., where spices are consumed far less.

Inflammation is the bodys natural response to irritants or things that may harm it. These include pathogens, stimuli, toxins, infections, and injuries.

But Dr. Robert H. Shmerling, the medical editor of Understanding Inflammation from Harvard Health Publishing and an associate professor of medicine at Harvard Medical School, says not all inflammation is bad. People think inflammation needs to be stomped out at all times, but it plays an essential role in healing and injury repair to keep your body safe and healthy, he wrote in Harvard Health Publishing.

Inflammation occurs in two main stages: acute and chronic. Shmerling explained that acute inflammation occurs when the bodys immune system releases white blood cells to protect the body. The body can experience swelling, redness, and painful joints as a result.

Acute inflammation is how your body fights infections and helps speed up the healing process, he said.

On the other hand, chronic inflammation occurs when injuries or infections persist and the body continues to produce white blood cells, which can attack the bodys healthy organs and tissues.

According to the 2018 study, chronic inflammation may lead to chronic diseases, such as cancer, arthritis, and diabetes. But researchers say spices can help to mitigate this. Congregate evidence suggests that a diet rich in plant-based agents including spices has the ability to prevent most of the chronic diseases, the studys authors wrote.

Kim Larson, a registered dietitian nutritionist certified by the National Board for Health and Wellness Coaching, agrees that spices have tremendous anti-inflammatory properties. I think people are often surprised at what a great anti-inflammatory source spices can be, she told Arthritis.org.

She continued: The more anti-inflammatory foods and spices you eat, the more you are tamping down on chronic inflammation.

A fan of yellow curry? You may already be reaping the benefits of turmeric. The spice is common in Indian and other South Asian cuisines. Studies have shown the yellow spices active chemical, called curcumin, has a number of anti-inflammatory benefits.

A 2017 study reviewed curcumins effects on human health. It found that curcumin can help to manage certain inflammatory conditions like arthritis and anxiety. It may also help to manage exercise-induced inflammation, such as sore muscles.

A similar study, released last year and published in Biomed Central, found curcumin was equally effective at relieving the symptoms of osteoarthritis as the anti-inflammatory drug NSAID diclofenac. Of those studied, 94 percent of those taking curcumin and 97 percent of those taking diclofenac reported at least a 50 percent improvement in symptoms.

Another popular spice used in Indian, Mexican, and South American dishescumin seed is a fruit of the flowering plant, which is native to India, China, the Middle East, and the eastern Mediterranean region.

Similar to turmeric, studies show the active ingredients in cumin seeds have antiseptic and anti-inflammatory effects.

If you suffer from painful, sore jointsyou just may want to opt for a little fresh ginger in your afternoon cup of tea.

A 2013 study published in the U.S. National Library of Medicine found ginger to have a number of anti-oxidative and anti-inflammatory effects on human health. The anticancer potential of ginger is well documented and its functional ingredients like gingerols, shogaol, and paradols are the valuable ingredients which can prevent various cancers, the studys authors wrote.

In addition to cancer, researchers also found that ginger has the potential to treat a number of ailments. These include degenerative disorders like arthritis, digestive health issues like indigestion and constipation, and cardiovascular disorders like hypertension.

If you can handle the heat, cayenne peppers are another terrific anti-inflammatory spice to cook with.

Cayenne and other hot chili peppers contain capsaicinoids an active compound called capsaicinoids, which have anti-inflammatory properties. Similar to turmeric, studies show capsaicin produces comparable anti-inflammatory effects as diclofenac.

If youre not already cooking with garlic, you definitely should be. Although the spice has a fairly strong taste and smell, studies have shown it has numerous health benefitsincluding reducing inflammation in the body.

Bad breath aside, garlic contains an anti-inflammatory compound called diallyl disulfide. The compound helps to minimize the effects of inflammation-causing cytokines, which are small proteins responsible for cell signaling.

If cayenne pepper is too spicy, opt for black pepper. The common cooking spice still packs a powerful anti-inflammatory punch and also has antibacterial and antioxidant benefits.

Known as the King of Spices, black pepper contains piperine, which studies show has anti-inflammatory and anti-arthritic properties.

Youll want to sprinkle extra cinnamon atop your toast and morning latte because the popular dessert spice is known to also help alleviate some symptoms caused by inflammation.

The cinnamon contains cinnamaldehydea compound that gives the sweet spice its flavor and smell. The compound has been shown to help prevent blood platelets from sticking together, as well as ease swelling.

When consumed on a regular basis, these seven spices may help to reduce the symptoms associated with inflammation for improved overall health.

Go here to read the rest:
Anti-Inflammatory Spices to Cook With Every Day - LIVEKINDLY